- Open Access
SARS-CoV-2 envelope protein triggers depression-like behaviors and dysosmia via TLR2-mediated neuroinflammation in mice
Journal of Neuroinflammation volume 20, Article number: 110 (2023)
Depression and dysosmia have been regarded as primary neurological symptoms in COVID-19 patients, the mechanism of which remains unclear. Current studies have demonstrated that the SARS-CoV-2 envelope (E) protein is a pro-inflammatory factor sensed by Toll-like receptor 2 (TLR2), suggesting the pathological feature of E protein is independent of viral infection. In this study, we aim to ascertain the role of E protein in depression, dysosmia and associated neuroinflammation in the central nervous system (CNS).
Depression-like behaviors and olfactory function were observed in both female and male mice receiving intracisternal injection of E protein. Immunohistochemistry was applied in conjunction with RT-PCR to evaluate glial activation, blood–brain barrier status and mediators synthesis in the cortex, hippocampus and olfactory bulb. TLR2 was pharmacologically blocked to determine its role in E protein-related depression-like behaviors and dysosmia in mice.
Intracisternal injection of E protein evoked depression-like behaviors and dysosmia in both female and male mice. Immunohistochemistry suggested that the E protein upregulated IBA1 and GFAP in the cortex, hippocampus and olfactory bulb, while ZO-1 was downregulated. Moreover, IL-1β, TNF-α, IL-6, CCL2, MMP2 and CSF1 were upregulated in both cortex and hippocampus, whereas IL-1β, IL-6 and CCL2 were upregulated in the olfactory bulb. Furtherly, inhibiting microglia, rather than astrocytes, alleviated depression-like behaviors and dysosmia induced by E protein. Finally, RT-PCR and immunohistochemistry suggested that TLR2 was upregulated in the cortex, hippocampus and olfactory bulb, the blocking of which mitigated depression-like behaviors and dysosmia induced by E protein.
Our study demonstrates that envelope protein could directly induce depression-like behaviors, dysosmia, and obvious neuroinflammation in CNS. TLR2 mediated depression-like behaviors and dysosmia induced by envelope protein, which could serve as a promising therapeutic target for neurological manifestation in COVID-19 patients.
The COVID-19 pandemic has dramatically impacted the world since the SARS-CoV-2 virus infection outbreak in 2019. Clinical symptoms of COVID-19 could involve several human body systems, apart from the most commonly known respiratory system symptoms. The COVID-19 infection can cause a series of neurological symptoms, including attention disorders, sleep disorders, short-term memory loss, seizures, strokes, headaches, dizziness, smell and taste loss, and neuropsychiatric symptoms, such as anxiety and depression [1,2,3,4,5,6,7,8]. Furthermore, brain MRI imaging of COVID-19 patients showed a decrease in overall brain size, prefrontal brain, and parahippocampal gyrus gray matter thickness. Additionally, changes of tissue damage markers in the primary olfactory cortex regions were more significant compared with the negative control group . Further pathological observation revealed that brain samples from patients with COVID-19 showed replication of SARS-CoV-2 in CNS and infection of glial cells by the virus . However, the relationship between SARS-CoV-2 infection and COVID-19 neurological symptoms remains unclear.
The SARS-CoV-2 virus has four structural proteins: the membrane protein, spike protein, nucleocapsid protein, and envelope protein (E) . The E is a small integral protein composed of only 75 amino acids. However, E involves many processes in the virus's life cycle, such as assembly, budding, envelope formation, and pathogenic mechanism . The E is highly expressed in infected cells during the virus's replication cycle . E plays a vital role in the production and maturation of the virus. Evidence reveals that recombinant coronavirus lacking E showed significantly decreased virus titers and offspring with impaired virus maturation or insufficient production and proliferation [14, 15]. Meanwhile, E, as a multifunctional protein, not only acts as a structural component in the virus capsid and participates in virus assembly, but also acts as a virulent toxin and participates in the pathogenesis of the virus [16, 17].
Previous evidence reported that the E protein of SARS-CoV-2 could bind to the Toll-like receptors (TLRs) and induce pulmonary inflammation . Additionally, the E protein is also necessary for the release of inflammatory cytokines during coronavirus infection. It was found that the E protein could interact with TLR2 receptors and induce the expression of tumor necrosis factor, interferon-γ, interleukin 6, and interleukin 1β in human peripheral blood mononuclear cells. The SARS-CoV-1 strain lacking the E protein was unable to activate the NF-κB signal transduction pathway, resulting in a significant decrease in the production of inflammatory cytokines . Combined the neurological SARS-CoV-2 infection with the essential role of E protein–TLRs interaction in the virus pathogenesis, we hypothesize that the COVID-19 patients’ dysosmia and depression symptoms might be mediated by the interaction of E protein with TLRs of glial cells.
Wild type C57BL/6 male and female mice (20–25 g; 6–8 weeks), purchased from the National Institutes for Food and Drug Control in China, were used in this study. Animals were housed under a 12-h light/12-h dark cycle with ad libitum access to food and water.
Sucrose preference test (SPT)
The mice were housed in cages with a two-bottle-choice setting for 48 h (one bottle for water and the other for 1.5% sucrose solution). In addition, the position of the two bottles was switched at 24 h. Water access was then deprived from the tested mice for 24 h. The two-bottle drinking setting was provided again for the tested mice for 2 h, during which the position of the two bottles was switched at 1 h. The ratio of sucrose solution consumed to the total fluid intake was determined as the sucrose preference .
Tail suspension test (TST)
The TST was performed as previously described. Briefly, each mouse was suspended by its tail with a short adhesive tape connected to a load cell that transmitted a signal corresponding to activity. The total test time was 6 min. After setting a low threshold, the duration of immobility was recorded and analyzed by tail suspension software (SOF-821, Med Associates) .
Forced swimming test (FST)
Mice were individually placed in a beaker (height: 19 cm; diameter: 14 cm) containing 14 cm of water (23 ± 2 °C). The total test duration was 6 min. The process was videotaped, and the immobility time in the last 4 min was scored by an experienced observer blinded to the experimental treatment. Floating or only slight movement to maintain balance was considered as immobility .
Olfactory measurement (OM)
On the first day, the mice were trained for 3 min in a cage containing sunflower seeds in four corners. Then, the mice were trained for 3 min again, but sunflower seeds were placed only in one corner. Following the training, the mice were separated from their dam and food was withheld for one day. Three 3-min trials were conducted on day 3. In trials 1 and 2, one sunflower seed was placed in the cage on bedding, each time in a different corner. In trial 3, a seed was buried under the bedding at the center of the cage. The latency to find the food was recorded. If mice could not to find a seed within 3 min, the latency to find food was recorded as 180 s. A shorter latency to find buried sunflower seed indicates better olfaction .
To observe the effects of E protein in CNS, mice received intracisternal injection of E protein. Briefly, E protein (0.2 μg/μl buffered in PBS, 5 μl) (ENN-C5128, Acro Biosystems) or Vehicle (PBS, 5 μl) was slowly injected into the cisterna magna using a specially made length-limited syringe [22,23,24]. To inhibit microglia and astrocytes, minocycline (a microglial inhibitor, 5 μg in 5 μl PBS, delivered daily for constructive 5 days prior to E protein application) (M9511, sigma) and L-α-aminoadipate (LAA, an astroglial toxin, 50 nmol buffered in 1N HCl and further diluted in PBS, delivered 1 h prior to E protein application) (A7275, sigma) were applied via intracisternal injection [25, 26]. To specifically block TLR2, C29 (a specific TLR2 inhibitor, 50 mg/kg, buffered in PBS containing 10% DMSO) was injected into the cisterna magna via syringe 1 h prior to E protein application. The timeline of drug delivery, behavior test, and tissue collection is depicted in Fig. 1.
Immunofluorescence (IF) was performed as previously described. Briefly, mice were anesthetized with intraperitoneal sodium pentobarbital injection (40 mg/kg) under aseptic condition and then transcardially perfused with ice-cold PBS followed by ice-cold paraformaldehyde. The whole brain from each tested mouse was collected, post-fixed in 4% paraformaldehyde at 4 °C for 2 h, then dehydrated in 30% sucrose at 4 °C. Then, these brain tissues were embedded in OCT (Tissue-Tek, Japan) and serially sectioned in a cryostat (Leica 2000, Germany) into 30-μm-thick slices. The tissue sections were blocked with 5% donkey serum containing 0.3% Triton X-100 for 1 h, and then primary antibodies were incubated at 4 °C overnight in a wet box. After washing in PBS buffer, secondary antibodies were incubated for 1 h at room temperature (primary antibodies list: ZO-1, ab 221547, abcam, 1:200; IBA1, ab5076, abcam, 1:1000; GFAP, ab53554, abcam, 1:1000; TLR2, ab209216, abcam, 1:200. Secondary antibody list: Donkey anti-Rabbit 488, A32790, Invitrogen, 1:500; Donkey anti-Mouse 488, A-21202, Invitrogen, 1:500; Donkey anti-Goat 488, ab150129, abcam, 1:500). The slides were then coverslipped by Mounting Medium solution containing DAPI (ZSJB-Bio, Beijing, China). Images were captured by a laser confocal microscopic imaging system under the same settings (TCS-SP8 STED 3X, Leica, Germany). The quantification for IF staining referred to previous studies . At least 10 sections from 3 randomly selected mice in each group were examined. The positive area of IBA1, GFAP, ZO-1 and TLR2 staining was measured with Image J.
Total RNAs from the cortex, hippocampus, and olfactory bulb were extracted using Trizol reagent (CW-bio, Beijing, China) and then reverse transcribed by RT Master Mix according to the instruction (Takara, Japan). Finally, qRT-PCR was performed using a CFX96™ Real-Time PCR Detection System (Bio-Rad, California, USA) with TB Green Premix Ex Taq (Takara, Japan). The primers used are listed in Additional file 4: Table S1.
Data values were presented as means with standard errors (mean ± SEM). Statistical analyses were performed by Graph Pad software. The Shapiro–Wilk test was applied to determine the normality for the parametric test. The Student’s t-test was used to determine the statistical difference between two groups. The criterion for statistical significance was a value of p < 0.05.
E protein induced depression-like behaviors and dysosmia in female and male mice
To identify the neuropathological effects of E protein, we applied intracisternal injection of E protein and evaluated the mental and olfactory status. The SPT, TST, and FST tests indicated that E protein in the CNS significantly induced depression-like behaviors in both female and male mice (Fig. 2A–C). Furthermore, the OM test showed that E protein increased the time to find the target food in both female and male mice, suggesting that E protein evoked olfactory impairment (Fig. 2D). Collectively, we observed typical depression-like behaviors and olfactory disturbances in COVID-19 patients as a result of E protein delivery to the CNS.
E protein triggered neuroinflammation and blood–brain barrier damage in cortex, hippocampus and olfactory bulb
Neuroinflammation has been regarded as a key cause of depressive and olfactory disorders, so we further systemically assessed the neuroinflammatory status in the cortex, hippocampus and olfactory bulb regions. IF staining for the microglia marker IBA1 suggested significant microglia activation induced by E protein in the cortex (Fig. 3A, B), hippocampus (CA1, CA3 and DG regions) (Fig. 3C–F), and olfactory bulb (Fig. 3G, H) in both male and female mice. Meanwhile, GFAP, the astrocytes marker, was also upregulated by E protein in the cortex (Fig. 4A, B), hippocampus (CA1, CA3 and DG regions) (Fig. 4C–F), and olfactory bulb (Fig. 4G, H). These results indicated that E protein triggered significant glial activation in the cortex, hippocampus and olfactory bulb regions. The destruction of the blood–brain barrier (BBB) plays a critical role in the formation of neuroinflammation; therefore, we also tested the expression of tight junction marker ZO-1 to evaluate BBB status. The IF staining showed a significant decrease of ZO-1 expression in the cortex (Fig. 5A, B), hippocampus (CA1, CA3 and DG regions) (Fig. 5C–F), and olfactory bulb (Fig. 5G, H) induced by E protein injection in both female and male mice. Further, we screened the typical neuroinflammatory mediators in the relative brain areas. The RT-PCR results showed that the mRNA expression levels of IL-1β, TNF-α, IL-6, CCL2, MMP2 and CSF1 were upregulated in the cortex and hippocampus. Meanwhile, the mRNA levels of IL-1β, IL-6 and CCL2 were increased in the olfactory blob (Fig. 6). Together, the above results suggested the occurrence of neuroinflammation induced by E protein in brain regions related to depression-like behaviors and dysosmia.
Inhibiting microglia mitigated depression-like behaviors and dysosmia induced by E protein
Both microglia and astrocytes are essential components in neuroinflammation and neuropathological process. To further investigate the contribution of microglia and astrocytes in E-induced depression-like behaviors and dysosmia symptoms, we used minocycline and LAA to inhibit microglia and astrocytes, respectively, before E protein administration. Immunofluorescence staining suggested that minocycline significantly downregulated the expression of IBA-1 in the cortex, hippocampus, and olfactory bulb (Fig. 7A–C). Similarly, the GFAP molecule expression was inhibited by LAA (Additional file 1: Figure S1A-C). The SPT, TST, and FST tests showed that microglia inhibition by minocycline could successfully alleviate E-induced depression-like behaviors and olfactory disorder in mice (Fig. 7D–G). However, the astrocytes inhibition by LAA failed to recover the depression-like behaviors and olfactory disorder in mice at our observed time point (Additional file 1: Figure S1D-G). Furtherly, minocycline blocked the pro-inflammatory cytokines production induced by E protein (Additional file 2: Figure S2), which might serve as the key source of depressive behavior and dysosmia. Taken together, these results indicated that it was microglia rather than astrocytes that mediated E-induced depression-like behaviors and dysosmia.
E protein upregulated TLRs in cortex, hippocampus and olfactory bulb
As an exogenous protein, E protein may be recognized by Toll-like receptors, a group of classic pattern recognition receptors. To identify the possible interaction between TLRs and E protein, we investigated the TLRs mRNA expression in associated brain regions. The RT-PCR results showed that TLR2, TLR3, TLR5, and TLR8 mRNA expression were upregulated in the cortex (Fig. 8A). Additionally, the E protein injection also significantly upregulated TLR2, TLR3, TLR4, TLR5 and TLR8 in the hippocampus (Fig. 8B). In the olfactory bulb, the TLR2, TLR7 and TLR8 mRNA expression levels were upregulated by E protein injection (Fig. 8C). These results indicated that the E protein might take effect via activating the TLRs-dependent signaling pathway. Given that TLR2 was upregulated among three brain regions and its crucial role in microglia function, we further investigated the distribution and role of TLR2 in E-related depression-like behaviors and dysosmia.
Blocking TLR2 alleviated depression-like behaviors and dysosmia induced by E protein
We hypothesized that the E protein triggered neuroinflammation and evoked depression-like behaviors and dysosmia symptoms via TLR2 in CNS. Firstly, IF staining of TLR2 suggested that E protein application to the CNS significantly upregulated TLR2 expression in the cortex (Fig. 9A, B), hippocampus (CA1, CA3 and DG regions) (Fig. 9C–F), and olfactory bulb (Fig. 9G, H). Secondly, we pharmacologically blocked TLR2 using C29a, a specific TLR2 blocker. Simultaneously, the activation of microglia (Fig. 10A–C) and the synthesis of pro-inflammatory cytokines (Additional file 3: Figure S3) were inhibited by C29. The SPT, TST, and FST tests indicated the depression-like behaviors induced by E protein were alleviated by C29 (Fig. 10D–F). Additionally, the shortened latency time in the OM test suggested that the olfactory disorder in mice was also relieved by C29 (Fig. 10G). Overall, these results revealed that blocking TLR2 could alleviate E-induced dysosmia and depression-like behaviors.
Patients with COVID-19 suffer from various neurological and psychiatric symptoms such as dysosmia and depression [28, 29]. The cellular and molecular mechanisms are still elusive, though. The recent discovery provides evidence in support of the notion that the SARS-CoV-2 envelope protein may cause a neuroinflammatory response separate from viral infection [18, 30]. Given these pro-inflammatory properties of the E protein and that neuroinflammation often leads to olfactory dysfunction and mood disorder, we examined the ability of the E protein to trigger inflammatory responses in CNS in vivo and the behavioral sequelae of that response. We demonstrated that intracisternal injection of E protein led to depression-like behaviors and dysosmia as well as neuroinflammation in CNS of mice. Our results suggest that several neurological and psychiatric disorders observed in COVID-19 patients can be mediated by the E protein during SARS-CoV-2 infection.
Hyperactivation of the neuroimmune system is closely related to mood disorders and olfactory dysfunction. There is mounting evidence that microglia play an etiological role in this process [31, 32]. Depression is considered a microglia-associated disorder. Suicidal people and depressive patients exhibit notably elevated microglia activation [33, 34]. Several depression-related brain regions have shown sustained microglial activation exhibiting high amounts of pro-inflammatory cytokines [35,36,37]. Microglial cells are highly concentrated in hippocampus, particularly in the CA1 region, and activation of these cells has been linked to the pathophysiology of major depressive disorder . Depressive-like behaviors were reduced by inhibiting microglial activation and neuroinflammation . Some clinical antidepressants, such as nonsteroidal anti-inflammatory drugs, appear to reduce the symptoms of depression by preventing the activation of microglia [40,41,42]. In addition, CNS inflammation is one of the etiologies of olfactory disorders . Olfaction is a crucial sense controlled by the olfactory epithelium's perception of odor molecules, which is then transported to the olfactory bulb via olfactory nerves and processed in the brain . There are lots of microglia in the olfactory bulb. Microgliosis is frequently observed in the olfactory bulb of olfactory dysfunction animals [45, 46]. Olfactory impairments may be caused by the microglial reaction in the olfactory bulb which leads to the loss of neuroblasts . As we observed, the inhibition of microglia effectively suppressed the inflammatory responses in associated brain regions (Additional file 2: Figure S2) and alleviated the depression-like behaviors and olfactory dysfunction induced by the E protein.
The E protein induces potent inflammatory responses as a virulence factor . Microglia and astrocytes were activated by intracisternal injection of the E protein. SARS-CoV-2 virus caused microglial activation and astrogliosis, according to a postmortem case study . Microglia and astrocytes are CNS resident cells and play a crucial role in homeostasis and neuroinflammation . We found that the inhibition of microglia, but not astrocytes, alleviated the E protein-induced depression-like behaviors and olfactory disorder. As the innate immune cells in the brain, microglia are more sensitive to pathogens than astrocytes and serve as the main mediators of neuroinflammation . In response to CNS injury, microglial activation is essential for host defense and neuron survival . However, persistent activation and dysregulation of microglia may result in deleterious and neurotoxic consequences by overproduction of a variety of cytotoxic factors such as TNF-α . Toxins and pathological stimuli injure neurons, which is enhanced and amplified by overactive microglia . This then further causes more extensive damage to nearby neurons and ultimately promotes pathogenic outcomes [55, 56].
On the other hand, both microglia and astrocytes can release pro-inflammatory mediators upon activation. In line with these findings, the E protein showed elevated expression of pro-inflammatory cytokines IL-1β and IL-6 in cortex, hippocampus, and olfactory bulb. Recent findings showed that increased levels of IL-1β and IL-6 were discovered in the cerebral fluid of patients with COVID-19 infection and neurological symptoms [57, 58]. Importantly, IL-1β and IL-6 have been identified as targets for alleviating the clinical condition, because they are thought to produce detrimental effects including the neurotoxic effect and inflammation. IL-1β has various biological activities. It increases neuronal apoptosis as well as neuronal loss by NMDA-evoked, glia-triggered, and/or proNGF-mediated pathways [59,60,61,62]. IL-6 also has been linked to neuronal cell death . Furthermore, we observed that the E protein reduced the expression of ZO-1 in various brain regions. IL-1β and IL-6 have been shown to enhance blood–brain barrier permeability through cytokines-induced tight junction degradation, particularly ZO-1 and claudin-5 [64,65,66]. Alteration of the BBB integrity increases the opportunity for the viruses and cytokines to pass the BBB and facilitate the infiltration of periphery immune cells into the CNS, resulting in brain injury and exacerbating neuropsychiatric symptoms [67, 68].
The E protein may induce the production of inflammatory factors through two potential mechanisms. TLR2 can sense the E protein [18, 69]. The E protein specifically interacts with the TLR2 pathway, activating NF-κB and inducing the release of pro-inflammatory cytokines and inflammatory chemokines. Additionally, it was found that the SARS-CoV envelope protein interacted with syntenin of the host cell. This interaction caused syntenin to be redistributed to the cytoplasm, where it caused the upregulation of inflammatory cytokines . This would cause an exacerbated immune response, leading to tissue damage, edema, and ultimately the characteristic acute respiratory distress syndrome, which was consistent with the histopathological characteristics induced by the SARS-CoV-2 E protein in the mouse spleen and lung .
TLRs identify pathogen-associated molecular patterns (PAMPs) and trigger immune responses on interaction with infectious pathogens. TLR1–9 are expressed in microglia. The expression of TLRs in microglia is controlled in response to pathogens . Microglial activation and neurotoxicity have been connected to TLRs [72, 73]. Several TLRs (TLR1, TLR2, TLR4, etc.) have an association with disease progression in patients with COVID-19 . In particular, TLR2, which can sense the E protein, is necessary for inflammatory responses to coronavirus. We also found that the E protein upregulated TLRs in multiple brain regions and triggered microglial inflammatory response via TLR2 in vivo. TLR2 is crucial for the microglia in response to viruses . TLR2 activation induced microglia to release NO and other cytotoxic substances through multiple ligands .
This study has several limitations. We found that the E protein caused neuroinflammation by activating TLR2 and led to depression-like behaviors and dysosmia. Although C29 simultaneously inhibited the activation of microglia while suppressing TLR2, given that TLR2 receptors are expressed in both astrocytes and neurons, it would be a more explicit approach to use the Cre-loxP system to further knock out TLR2 in microglia. In the CNS, microglia constantly monitor the microenvironment and produce substances that have an impact on nearby astrocytes and neurons . Although the interplay between glial cells and neurons is crucial in brain pathophysiology , it is impossible to disregard the immediate impact of SARS-CoV-2 on neurons. SARS-CoV-2 can infect neurons directly [78, 79]. Whether the E protein causes injury to neurons and there is a relationship between this effect and the neurological complications of SARS-CoV-2 deserve further exploration.
Availability of data and materials
There are no data, software, databases, and application/tools available apart from those reported in the present study. All data are provided in the manuscript and supplementary data section.
Central nervous system
- E protein:
SARS-CoV-2 envelope protein
Sucrose preference test
Forced swimming test
Tail suspension test
Pathogen-associated molecular patterns
Toll-like receptor 2
Solomon IH, Normandin E, Bhattacharyya S, Mukerji SS, Keller K, Ali AS, Adams G, Hornick JL, Padera RF Jr, Sabeti P. Neuropathological features of covid-19. N Engl J Med. 2020;383:989–92.
Saladino V, Algeri D, Auriemma V. The psychological and social impact of covid-19: new perspectives of well-being. 2020; 11.
Mazza MG, Palladini M, De Lorenzo R, Magnaghi C, Poletti S, Furlan R, Ciceri F, Rovere-Querini P, Benedetti F. Persistent psychopathology and neurocognitive impairment in COVID-19 survivors: effect of inflammatory biomarkers at three-month follow-up. Brain Behav Immun. 2021;94:138–47.
Mazza MG, De Lorenzo R, Conte C, Poletti S, Vai B, Bollettini I, Melloni EMT, Furlan R, Ciceri F, Rovere-Querini P, Benedetti F. Anxiety and depression in COVID-19 survivors: role of inflammatory and clinical predictors. Brain Behav Immun. 2020;89:594–600.
Schou TM, Joca S, Wegener G, Bay-Richter C. Psychiatric and neuropsychiatric sequelae of COVID-19—a systematic review. Brain Behav Immun. 2021;97:328–48.
Chen F, Zheng D, Liu J, Gong Y, Guan Z, Lou D. Depression and anxiety among adolescents during COVID-19: a cross-sectional study. Brain Behav Immun. 2020;88:36–8.
Su S, Cui H, Wang T, Shen X, Ma C. Pain: a potential new label of COVID-19. Brain Behav Immun. 2020;87:159–60.
Bartley CM, Johns C, Ngo TT, Dandekar R, Loudermilk RL, Alvarenga BD, Hawes IA, Zamecnik CR, Zorn KC, Alexander JR, et al. Anti-SARS-CoV-2 and autoantibody profiles in the cerebrospinal fluid of 3 teenaged patients with COVID-19 and subacute neuropsychiatric symptoms. JAMA Neurol. 2021;78:1503–9.
Smith S. UKB brain imaging covid study. Zenodo; 2022.
Crunfli F, Carregari VC, Veras FP, Silva LS, Nogueira MH, Antunes A, Vendramini PH, Valença AGF, Brandão-Teles C, Zuccoli GDS, et al. Morphological, cellular, and molecular basis of brain infection in COVID-19 patients. Proc Natl Acad Sci U S A. 2022;119: e2200960119.
Brian DA, Baric RS. Coronavirus genome structure and replication. In: Enjuanes L, editor. Coronavirus replication and reverse genetics. Berlin, Heidelberg: Springer, Berlin Heidelberg; 2005. p. 1–30.
Schoeman D, Fielding BC. Coronavirus envelope protein: current knowledge. Virol J. 2019;16:69.
Venkatagopalan P, Daskalova SM, Lopez LA, Dolezal KA, Hogue BG. Coronavirus envelope (E) protein remains at the site of assembly. Virology. 2015;478:75–85.
Ortego J, Ceriani JE, Patiño C, Plana J, Enjuanes L. Absence of E protein arrests transmissible gastroenteritis coronavirus maturation in the secretory pathway. Virology. 2007;368:296–308.
DeDiego ML, Alvarez E, Almazán F, Rejas MT, Lamirande E, Roberts A, Shieh WJ, Zaki SR, Subbarao K, Enjuanes L. A severe acute respiratory syndrome coronavirus that lacks the E gene is attenuated in vitro and in vivo. J Virol. 2007;81:1701–13.
Mandala VS, McKay MJ, Shcherbakov AA, Dregni AJ, Kolocouris A, Hong M. Structure and drug binding of the SARS-CoV-2 envelope protein transmembrane domain in lipid bilayers. Nat Struct Mol Biol. 2020;27:1202–8.
Cao Y, Yang R, Lee I, Zhang W, Sun J, Wang W, Meng X. Characterization of the SARS-CoV-2 E protein: sequence, structure, viroporin, and inhibitors. Protein Sci. 2021;30:1114–30.
Zheng M, Karki R, Williams EP, Yang D, Fitzpatrick E, Vogel P, Jonsson CB, Kanneganti T-D. TLR2 senses the SARS-CoV-2 envelope protein to produce inflammatory cytokines. Nat Immunol. 2021;22:829–38.
DeDiego ML, Nieto-Torres Jose L, Regla-Nava Jose A, Jimenez-Guardeño Jose M, Fernandez-Delgado R, Fett C, Castaño-Rodriguez C, Perlman S, Enjuanes L. Inhibition of NF-κB-mediated inflammation in severe acute respiratory syndrome coronavirus-infected mice increases survival. J Virol. 2014;88:913–24.
Liu S, Xiu J, Zhu C, Meng K, Li C, Han R, Du T, Li L, Xu L, Liu R, et al. Fat mass and obesity-associated protein regulates RNA methylation associated with depression-like behavior in mice. Nat Commun. 2021;12:6937.
Hung YF, Chen CY, Li WC, Wang TF, Hsueh YP. Tlr7 deletion alters expression profiles of genes related to neural function and regulates mouse behaviors and contextual memory. Brain Behav Immun. 2018;72:101–13.
Frank MG, Nguyen KH, Ball JB, Hopkins S, Kelley T, Baratta MV, Fleshner M, Maier SF. SARS-CoV-2 spike S1 subunit induces neuroinflammatory, microglial and behavioral sickness responses: evidence of PAMP-like properties. Brain Behav Immun. 2022;100:267–77.
Li F, Yang W, Jiang H, Guo C, Huang AJW, Hu H, Liu Q. TRPV1 activity and substance P release are required for corneal cold nociception. Nat Commun. 2019;10:5678.
Wang F, Trier AM, Li F, Kim S, Chen Z, Chai JN, Mack MR, Morrison SA, Hamilton JD, Baek J, et al. A basophil-neuronal axis promotes itch. Cell. 2021;184:422-440.e417.
Chen G, Luo X, Qadri MY, Berta T, Ji RR. Sex-dependent glial signaling in pathological pain: distinct roles of spinal microglia and astrocytes. Neurosci Bull. 2018;34:98–108.
Zhao J, Blaeser AS, Levy D. Astrocytes mediate migraine-related intracranial meningeal mechanical hypersensitivity. Pain. 2021;162:2386–96.
Su W, Cui H, Wu D, Yu J, Ma L, Zhang X, Huang Y, Ma C. Suppression of TLR4-MyD88 signaling pathway attenuated chronic mechanical pain in a rat model of endometriosis. J Neuroinflammation. 2021;18:65.
Baig AM. Neurological manifestations in COVID-19 caused by SARS-CoV-2. CNS Neurosci Ther. 2020;26:499–501.
Pezzini A, Padovani A. Lifting the mask on neurological manifestations of COVID-19. Nat Rev Neurol. 2020;16:636–44.
Ju J, Su Y, Zhou Y, Wei H, Xu Q. The SARS-CoV-2 envelope protein disrupts barrier function in an in vitro human blood-brain barrier model. Front Cell Neurosci. 2022;16: 897564.
Frick LR, Williams K, Pittenger C. Microglial dysregulation in psychiatric disease. Clin Dev Immunol. 2013;2013: 608654.
Kim J, Choi Y, Ahn M, Jung K, Shin T. Olfactory dysfunction in autoimmune central nervous system neuroinflammation. Mol Neurobiol. 2018;55:8499–508.
Schnieder TP, Trencevska I, Rosoklija G, Stankov A, Mann JJ, Smiley J, Dwork AJ. Microglia of prefrontal white matter in suicide. J Neuropathol Exp Neurol. 2014;73:880–90.
Steiner J, Bielau H, Brisch R, Danos P, Ullrich O, Mawrin C, Bernstein HG, Bogerts B. Immunological aspects in the neurobiology of suicide: elevated microglial density in schizophrenia and depression is associated with suicide. J Psychiatr Res. 2008;42:151–7.
Liu LL, Li JM, Su WJ, Wang B, Jiang CL. Sex differences in depressive-like behaviour may relate to imbalance of microglia activation in the hippocampus. Brain Behav Immun. 2019;81:188–97.
Zhang Y, Su WJ, Chen Y, Wu TY, Gong H, Shen XL, Wang YX, Sun XJ, Jiang CL. Effects of hydrogen-rich water on depressive-like behavior in mice. Sci Rep. 2016;6:23742.
Sugama S, Takenouchi T, Fujita M, Conti B, Hashimoto M. Differential microglial activation between acute stress and lipopolysaccharide treatment. J Neuroimmunol. 2009;207:24–31.
Walker FR, Nilsson M, Jones K. Acute and chronic stress-induced disturbances of microglial plasticity, phenotype and function. Curr Drug Targets. 2013;14:1262–76.
Zhao Y, Wang Q, Jia M, Fu S, Pan J, Chu C, Liu X, Liu X, Liu Z. (+)-Sesamin attenuates chronic unpredictable mild stress-induced depressive-like behaviors and memory deficits via suppression of neuroinflammation. J Nutr Biochem. 2019;64:61–71.
Jiang B, Wang H, Wang JL, Wang YJ, Zhu Q, Wang CN, Song L, Gao TT, Wang Y, Meng GL, et al. Hippocampal salt-inducible kinase 2 plays a role in depression via the CREB-regulated transcription coactivator 1-cAMP response element binding-brain-derived neurotrophic factor pathway. Biol Psychiatry. 2019;85:650–66.
Zhong Q, Yu H, Huang C, Zhong J, Wang H, Xu J, Cheng Y. FCPR16, a novel phosphodiesterase 4 inhibitor, produces an antidepressant-like effect in mice exposed to chronic unpredictable mild stress. Prog Neuropsychopharmacol Biol Psychiatry. 2019;90:62–75.
Köhler O, Benros ME, Nordentoft M, Farkouh ME, Iyengar RL, Mors O, Krogh J. Effect of anti-inflammatory treatment on depression, depressive symptoms, and adverse effects: a systematic review and meta-analysis of randomized clinical trials. JAMA Psychiat. 2014;71:1381–91.
Seo Y, Kim HS, Kang KS. Microglial involvement in the development of olfactory dysfunction. J Vet Sci. 2018;19:319–30.
Mori K, Nagao H, Yoshihara Y. The olfactory bulb: coding and processing of odor molecule information. Science. 1999;286:711–5.
Seo Y, Kim HS, Kang I, Choi SW, Shin TH, Shin JH, Lee BC, Lee JY, Kim JJ, Kook MG, Kang KS. Cathepsin S contributes to microglia-mediated olfactory dysfunction through the regulation of Cx3cl1-Cx3cr1 axis in a Niemann-Pick disease type C1 model. Glia. 2016;64:2291–305.
Hovakimyan M, Meyer A, Lukas J, Luo J, Gudziol V, Hummel T, Rolfs A, Wree A, Witt M. Olfactory deficits in Niemann-Pick type C1 (NPC1) disease. PLoS ONE. 2013;8: e82216.
Seo Y, Kim HS, Shin Y, Kang I, Choi SW, Yu KR, Seo KW, Kang KS. Excessive microglial activation aggravates olfactory dysfunction by impeding the survival of newborn neurons in the olfactory bulb of Niemann-Pick disease type C1 mice. Biochim Biophys Acta. 2014;1842:2193–203.
Xia B, Shen X, He Y, Pan X, Liu FL, Wang Y, Yang F, Fang S, Wu Y, Duan Z, et al. SARS-CoV-2 envelope protein causes acute respiratory distress syndrome (ARDS)-like pathological damages and constitutes an antiviral target. Cell Res. 2021;31:847–60.
Matschke J, Lütgehetmann M, Hagel C, Sperhake JP, Schröder AS, Edler C, Mushumba H, Fitzek A, Allweiss L, Dandri M, et al. Neuropathology of patients with COVID-19 in Germany: a post-mortem case series. Lancet Neurol. 2020;19:919–29.
Liu LR, Liu JC, Bao JS, Bai QQ, Wang GQ. Interaction of microglia and astrocytes in the neurovascular unit. Front Immunol. 2020;11:1024.
Garland EF, Hartnell IJ, Boche D. Microglia and astrocyte function and communication: what do we know in humans? Front Neurosci. 2022;16: 824888.
Polazzi E, Contestabile A. Reciprocal interactions between microglia and neurons: from survival to neuropathology. Rev Neurosci. 2002;13:221–42.
Sawada M, Kondo N, Suzumura A, Marunouchi T. Production of tumor necrosis factor-alpha by microglia and astrocytes in culture. Brain Res. 1989;491:394–7.
Block ML, Hong JS. Microglia and inflammation-mediated neurodegeneration: multiple triggers with a common mechanism. Prog Neurobiol. 2005;76:77–98.
Teismann P, Tieu K, Cohen O, Choi DK, Wu DC, Marks D, Vila M, Jackson-Lewis V, Przedborski S. Pathogenic role of glial cells in Parkinson’s disease. Mov Disord. 2003;18:121–9.
Vasek MJ, Garber C, Dorsey D, Durrant DM, Bollman B, Soung A, Yu J, Perez-Torres C, Frouin A, Wilton DK, et al. A complement-microglial axis drives synapse loss during virus-induced memory impairment. Nature. 2016;534:538–43.
Normandin E, Holroyd KB, Collens SI, Shaw BM, Siddle KJ, Adams G, Rudy M, Solomon IH, Anahtar MN, Lemieux JE, et al. Intrathecal inflammatory responses in the absence of SARS-CoV-2 nucleic acid in the CSF of COVID-19 hospitalized patients. J Neurol Sci. 2021;430: 120023.
Pilotto A, Masciocchi S, Volonghi I, De Giuli V, Caprioli F, Mariotto S, Ferrari S, Bozzetti S, Imarisio A, Risi B, et al. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) encephalitis is a cytokine release syndrome: evidences from cerebrospinal fluid analyses. Clin Infect Dis. 2021;73:e3019–26.
Lu KT, Wang YW, Yang JT, Yang YL, Chen HI. Effect of interleukin-1 on traumatic brain injury-induced damage to hippocampal neurons. J Neurotrauma. 2005;22:885–95.
Long-Smith CM, Collins L, Toulouse A, Sullivan AM, Nolan YM. Interleukin-1β contributes to dopaminergic neuronal death induced by lipopolysaccharide-stimulated rat glia in vitro. J Neuroimmunol. 2010;226:20–6.
Ye L, Huang Y, Zhao L, Li Y, Sun L, Zhou Y, Qian G, Zheng JC. IL-1β and TNF-α induce neurotoxicity through glutamate production: a potential role for neuronal glutaminase. J Neurochem. 2013;125:897–908.
Choi S, Friedman WJ. Interleukin-1β enhances neuronal vulnerability to proNGF-mediated apoptosis by increasing surface expression of p75(NTR) and sortillin. Neuroscience. 2014;257:11–9.
Conroy SM, Nguyen V, Quina LA, Blakely-Gonzales P, Ur C, Netzeband JG, Prieto AL, Gruol DL. Interleukin-6 produces neuronal loss in developing cerebellar granule neuron cultures. J Neuroimmunol. 2004;155:43–54.
Lucas SM, Rothwell NJ, Gibson RM. The role of inflammation in CNS injury and disease. Br J Pharmacol. 2006;147(Suppl 1):S232-240.
Desai TR, Leeper NJ, Hynes KL, Gewertz BL. Interleukin-6 causes endothelial barrier dysfunction via the protein kinase C pathway. J Surg Res. 2002;104:118–23.
Klein RS, Garber C, Funk KE, Salimi H, Soung A, Kanmogne M, Manivasagam S, Agner S, Cain M. Neuroinflammation during RNA viral infections. Annu Rev Immunol. 2019;37:73–95.
Kempuraj D, Thangavel R, Selvakumar GP, Zaheer S, Ahmed ME, Raikwar SP, Zahoor H, Saeed D, Natteru PA, Iyer S, Zaheer A. Brain and peripheral atypical inflammatory mediators potentiate neuroinflammation and neurodegeneration. Front Cell Neurosci. 2017;11:216.
John GR, Lee SC, Brosnan CF. Cytokines: powerful regulators of glial cell activation. Neuroscientist. 2003;9:10–22.
Planès R, Bert JB, Tairi S, BenMohamed L, Bahraoui E. SARS-CoV-2 envelope (E) protein binds and activates TLR2 pathway: a novel molecular target for COVID-19 interventions. Viruses. 2022;14:141.
Jimenez-Guardeño JM, Nieto-Torres JL, DeDiego ML, Regla-Nava JA, Fernandez-Delgado R, Castaño-Rodriguez C, Enjuanes L. The PDZ-binding motif of severe acute respiratory syndrome coronavirus envelope protein is a determinant of viral pathogenesis. PLoS Pathog. 2014;10: e1004320.
McKimmie CS, Fazakerley JK. In response to pathogens, glial cells dynamically and differentially regulate Toll-like receptor gene expression. J Neuroimmunol. 2005;169:116–25.
Jack CS, Arbour N, Manusow J, Montgrain V, Blain M, McCrea E, Shapiro A, Antel JP. TLR signaling tailors innate immune responses in human microglia and astrocytes. J Immunol. 2005;175:4320–30.
Olson JK, Miller SD. Microglia initiate central nervous system innate and adaptive immune responses through multiple TLRs. J Immunol. 2004;173:3916–24.
Aravalli RN, Hu S, Rowen TN, Palmquist JM, Lokensgard JR. Cutting edge: TLR2-mediated proinflammatory cytokine and chemokine production by microglial cells in response to herpes simplex virus. J Immunol. 2005;175:4189–93.
Ebert S, Gerber J, Bader S, Mühlhauser F, Brechtel K, Mitchell TJ, Nau R. Dose-dependent activation of microglial cells by Toll-like receptor agonists alone and in combination. J Neuroimmunol. 2005;159:87–96.
Gomez-Nicola D, Perry VH. Microglial dynamics and role in the healthy and diseased brain: a paradigm of functional plasticity. Neuroscientist. 2015;21:169–84.
Zhang X, Dong H, Li N, Zhang S, Sun J, Zhang S, Qian Y. Activated brain mast cells contribute to postoperative cognitive dysfunction by evoking microglia activation and neuronal apoptosis. J Neuroinflammation. 2016;13:127.
Lyoo KS, Kim HM, Lee B, Che YH, Kim SJ, Song D, Hwang W, Lee S, Park JH, Na W, et al. Direct neuronal infection of SARS-CoV-2 reveals cellular and molecular pathology of chemosensory impairment of COVID-19 patients. Emerg Microbes Infect. 2022;11:406–11.
Beckman D, Bonillas A, Diniz GB, Ott S, Roh JW, Elizaldi SR, Schmidt BA, Sammak RL, Van Rompay KKA, Iyer SS, Morrison JH. SARS-CoV-2 infects neurons and induces neuroinflammation in a non-human primate model of COVID-19. Cell Rep. 2022;41: 111573.
This work was supported by National High Level Hospital Clinical Research Funding (Scientific Research Seed Fund of Peking University First Hospital): 2022SF20 (Recipient: Wenliang Su) and National High-Level Hospital Clinical Research Funding (High-Quality Clinical Research Project of Peking University First Hospital): 2022CR74 (Recipient: Dongliang Mu).
Ethics approval and consent to participate
The experimental procedures were approved by the Peking University Biomedical Ethics Committee experimental animal ethics branch (NO: J2022130).
Consent for publication
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Additional file 1: Figure S1.
Inhibition of astrocytes did not alleviate depression-like behaviors and dysosmia induced by E protein. A. Representative images of GFAP expression in the cortex, hippocampus regions, and olfactory bulb from E protein-treated mice receiving Vehicle or LAA injection. B-C. Fluorescence area analysis showed that LAA significantly downregulated GFAP expression in the cortex, hippocampus, and olfactory bulb. D. The percentage of sucrose water consumption for PBS- or E protein-treated female and male mice receiving Vehicle or LAA injection. E. The immobility duration in TST test for PBS- or E protein-treated female and male mice receiving Vehicle or LAA injection. F. The immobility duration in FST test for PBS- or E protein-treated female and male mice receiving Vehicle or LAA injection. G. The latency time for discovering the sunflower seed in olfactory measurement in PBS- or E protein-treated female and male mice receiving Vehicle or LAA injection. n ≥ 6 per group; **p < 0.01, ***p< 0.001, ****p < 0.0001; n.s., no significance; Student’s t-test.
Additional file 2: Figure S2.
Inhibition of microglia by Minocycline attenuated the expression of neuroinflammatory mediators induced by E protein. A-B. qRT-PCR analysis showed that intracisternal injection of Minocycline downregulated IL-1β, TNF-α, IL-6, CCL2, MMP2, and CSF1 in the cortex and hippocampus. C. qRT-PCR analysis showed that intracisternal injection of Minocycline downregulated IL-1β, IL-6, and CCL2 in the olfactory bulb. n = 4; **p < 0.01, ***p < 0.001, ****p < 0.0001; n.s., no significance; Student’s t-test.
Additional file 3: Figure S3.
Blocking TLR2 by C29 attenuated the expression of neuroinflammatory mediators induced by E protein. A-B. qRT-PCR analysis showed that intracisternal injection of C29 downregulated IL-1β, TNF-α, IL-6, CCL2, MMP2, and CSF1 in the cortex and hippocampus. C. qRT-PCR analysis showed that intracisternal injection of C29 downregulated IL-1β, IL-6, and CCL2 in the olfactory bulb. n = 4; *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001; n.s., no significance; Student’s t-test.
Additional file 4: Table S1.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Su, W., Ju, J., Gu, M. et al. SARS-CoV-2 envelope protein triggers depression-like behaviors and dysosmia via TLR2-mediated neuroinflammation in mice. J Neuroinflammation 20, 110 (2023). https://doi.org/10.1186/s12974-023-02786-x
- E protein